Stem definition | Drug id | CAS RN |
---|---|---|
2657 | 55142-85-3 |
Dose | Unit | Route |
---|---|---|
0.50 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.81 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 80 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Oct. 31, 1991 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 61.38 | 30.64 | 46 | 1233 | 199575 | 50404270 |
Sopor | 50.66 | 30.64 | 19 | 1260 | 19860 | 50583985 |
Hyponatraemic syndrome | 42.97 | 30.64 | 8 | 1271 | 536 | 50603309 |
Hyperkalaemia | 40.21 | 30.64 | 21 | 1258 | 48068 | 50555777 |
Apraxia | 40.03 | 30.64 | 9 | 1270 | 1536 | 50602309 |
Hypercreatininaemia | 39.15 | 30.64 | 7 | 1272 | 374 | 50603471 |
Cerebral haemorrhage | 35.22 | 30.64 | 16 | 1263 | 27036 | 50576809 |
Hypochloraemia | 34.13 | 30.64 | 8 | 1271 | 1639 | 50602206 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 56.07 | 26.30 | 57 | 1348 | 197328 | 29375794 |
Sopor | 50.03 | 26.30 | 19 | 1386 | 10915 | 29562207 |
Slow speech | 49.94 | 26.30 | 11 | 1394 | 905 | 29572217 |
Intentional self-injury | 40.77 | 26.30 | 17 | 1388 | 12444 | 29560678 |
Alcohol interaction | 38.13 | 26.30 | 11 | 1394 | 2692 | 29570430 |
Melaena | 36.30 | 26.30 | 21 | 1384 | 31155 | 29541967 |
Hyponatraemia | 31.76 | 26.30 | 26 | 1379 | 67607 | 29505515 |
Electrocardiogram QT prolonged | 30.94 | 26.30 | 20 | 1385 | 36117 | 29537005 |
Mechanical urticaria | 30.39 | 26.30 | 5 | 1400 | 84 | 29573038 |
Anaemia | 28.66 | 26.30 | 41 | 1364 | 200910 | 29372212 |
Coombs negative haemolytic anaemia | 27.62 | 26.30 | 5 | 1400 | 150 | 29572972 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug interaction | 102.83 | 24.36 | 102 | 2795 | 361981 | 64133854 |
Sopor | 90.89 | 24.36 | 38 | 2859 | 29623 | 64466212 |
Melaena | 61.31 | 24.36 | 35 | 2862 | 53513 | 64442322 |
Intentional self-injury | 53.21 | 24.36 | 26 | 2871 | 29018 | 64466817 |
Cerebral haemorrhage | 49.55 | 24.36 | 30 | 2867 | 51060 | 64444775 |
Anaemia | 49.43 | 24.36 | 72 | 2825 | 378608 | 64117227 |
Hyponatraemic syndrome | 46.81 | 24.36 | 10 | 2887 | 753 | 64495082 |
Hyponatraemia | 44.07 | 24.36 | 43 | 2854 | 148296 | 64347539 |
Slow speech | 41.80 | 24.36 | 11 | 2886 | 2026 | 64493809 |
Hyperkalaemia | 41.17 | 24.36 | 35 | 2862 | 101094 | 64394741 |
Drug abuse | 34.93 | 24.36 | 36 | 2861 | 132338 | 64363497 |
Alcohol interaction | 33.43 | 24.36 | 11 | 2886 | 4390 | 64491445 |
Hypertensive crisis | 32.40 | 24.36 | 16 | 2881 | 18232 | 64477603 |
Apraxia | 30.60 | 24.36 | 9 | 2888 | 2486 | 64493349 |
Electrocardiogram QT prolonged | 29.29 | 24.36 | 26 | 2871 | 79422 | 64416413 |
Hypoglycaemia | 28.43 | 24.36 | 27 | 2870 | 89865 | 64405970 |
Hypochloraemia | 27.78 | 24.36 | 8 | 2889 | 2053 | 64493782 |
Subdural haematoma | 25.96 | 24.36 | 16 | 2881 | 28038 | 64467797 |
Hypercreatininaemia | 24.64 | 24.36 | 6 | 2891 | 809 | 64495026 |
Haematidrosis | 24.60 | 24.36 | 4 | 2893 | 66 | 64495769 |
None
Source | Code | Description |
---|---|---|
ATC | B01AC05 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin |
FDA PE | N0000008832 | Decreased Platelet Aggregation |
FDA EPC | N0000175578 | Platelet Aggregation Inhibitor |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D065689 | Cytochrome P-450 CYP2C19 Inhibitors |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D005343 | Fibrinolytic Agents |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D010975 | Platelet Aggregation Inhibitors |
MeSH PA | D058914 | Purinergic Antagonists |
MeSH PA | D058919 | Purinergic P2 Receptor Antagonists |
MeSH PA | D058921 | Purinergic P2Y Receptor Antagonists |
CHEBI has role | CHEBI:48676 | fibrin modulating agent |
CHEBI has role | CHEBI:50248 | hematologic agents |
CHEBI has role | CHEBI:50249 | anticoagulants |
CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
CHEBI has role | CHEBI:68563 | ADP receptor subtype P2Y12 antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Percutaneous coronary intervention | indication | 415070008 | |
Cerebrovascular Occlusion | indication | ||
Subacute Stent Thrombosis Prevention | indication | ||
Prevention of Cerebral Thrombosis | indication | ||
Obstruction of bile duct | contraindication | 30144000 | |
Gastrointestinal ulcer | contraindication | 40845000 | |
Hyperlipidemia | contraindication | 55822004 | DOID:1168 |
Acute nephropathy | contraindication | 58574008 | |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Ascorbic acid deficiency | contraindication | 76169001 | |
Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
Congenital hypoplastic anemia | contraindication | 88854002 | DOID:1339 |
Leukemia, disease | contraindication | 93143009 | DOID:1240 |
Procedure on central nervous system | contraindication | 118679007 | |
Bleeding | contraindication | 131148009 | |
Arterial aneurysm | contraindication | 233981004 | |
Cerebral hemorrhage | contraindication | 274100004 | |
Lumbar puncture | contraindication | 277762005 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
Surgical procedure | contraindication | 387713003 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.18 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
P2Y purinoceptor 12 | GPCR | ANTAGONIST | WOMBAT-PK | CHEMBL | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 4.28 | WOMBAT-PK | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.85 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 6.75 | DRUG MATRIX | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 6.86 | DRUG MATRIX | |||||
Alpha-2C adrenergic receptor | GPCR | Ki | 6.77 | DRUG MATRIX | |||||
Cytochrome P450 2D6 | Enzyme | IC50 | 5.20 | DRUG MATRIX | |||||
Cytochrome P450 2A6 | Enzyme | Ki | 6.70 | WOMBAT-PK | |||||
Bile salt export pump | Transporter | IC50 | 4.13 | CHEMBL | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 6.18 | DRUG MATRIX | |||||
Cytochrome P450 2B6 | Enzyme | INHIBITOR | IC50 | 6.70 | IUPHAR | ||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.33 | WOMBAT-PK | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 5.70 | DRUG MATRIX | |||||
Bile salt export pump | Transporter | IC50 | 4.31 | CHEMBL |
ID | Source |
---|---|
4020513 | VUID |
N0000148235 | NUI |
D01028 | KEGG_DRUG |
53885-35-1 | SECONDARY_CAS_RN |
4020458 | VANDF |
4020513 | VANDF |
C0040207 | UMLSCUI |
CHEBI:9588 | CHEBI |
TIC | PDB_CHEM_ID |
CHEMBL833 | ChEMBL_ID |
CHEMBL1717 | ChEMBL_ID |
DB00208 | DRUGBANK_ID |
D013988 | MESH_DESCRIPTOR_UI |
5472 | PUBCHEM_CID |
7307 | IUPHAR_LIGAND_ID |
3908 | INN_ID |
OM90ZUW7M1 | UNII |
10594 | RXNORM |
2177 | MMSL |
31069 | MMSL |
5582 | MMSL |
d00514 | MMSL |
003610 | NDDF |
003611 | NDDF |
108971003 | SNOMEDCT_US |
386950000 | SNOMEDCT_US |
395904008 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Ticlopidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-0079 | TABLET, FILM COATED | 250 mg | ORAL | ANDA | 25 sections |